Cipla informs about company updates

28 Jan 2020 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informed that following the inspection by the United States Food and Drug Administration (USFDA) at the Invagen (US) manufacturing facility from December 2, 2019 to December 6, 2019, the Company has received the Establishment Inspection Report (EIR), indicating closure of the inspection. 

The above information is a part of company’s filings submitted to BSE.

Cipla Share Price

1510.95 10.85 (0.72%)
02-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.35
Dr. Reddys Lab 1255.45
Cipla 1510.95
Zydus Lifesciences 916.50
Lupin 2105.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×